Stock SILF HEMOGENYX PHARMACEUTICALS PLC
Add to a list
To use this feature you must be a member
Log inSign up

News Hemogenyx Pharmaceuticals Plc

Equities

SILF

GB00BYX3WZ24

Delayed London S.E.
Other stock markets
 05:29:28 2024-04-25 am EDT 		5-day change 1st Jan Change
1.566 GBX -2.64% Intraday chart for Hemogenyx Pharmaceuticals Plc -6.31% -31.93%
08:00am Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Feb. 29 Hemogenyx Pharmaceuticals raises money for leukaemia treatment AN

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Hemogenyx Pharmaceuticals discusses successful £3.5M capital raise as it advances HEMO-CAR-T program
AQ
Hemogenyx Pharmaceuticals raises money for leukaemia treatment
AN
Hemogenyx Pharmaceuticals Raises $4.2 Million via Share Placing
MT
Hemogenyx Pharmaceuticals achieves breakthrough with HEMO-CAR-T program, CBR platform
AQ
Hemogenyx Pharmaceuticals PLC Announces CBR Brain Delivery
AQ
Hemogenyx Pharmaceuticals Achieves Breakthrough in Brain Cancer Treatment
MT
Hemogenyx shares rise on potential for CBR to treat brain diseases
AN
Hemogenyx Pharmaceuticals plc Announces CBR Brain Delivery
CI
Hemogenyx Pharmaceuticals Tests Intranasal Delivery for Viral Infections Treatment
MT
Hemogenyx says CBR can be used intranasally to treat viral infections
AN
Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold
AN
US FDA Removes Clinical Hold on Hemogenyx Pharmaceuticals' Acute Myeloid Leukemia Treatment
MT
Hemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-T
CI
Hemogenyx Pharmaceuticals Obtains US Conditioning Patent
MT
Hemogenyx hails US patent application progress
AN
Hemogenyx Pharmaceuticals plc Announces Approval and Issuance of U.S. Conditioning Patent
CI
Hemogenyx Pharmaceuticals plc - Submission of Complete Response to Clinical Hold for HEMO-CAR-T IND
AQ
Hemogenyx Pharmaceuticals sends complete response on HEMO-CAR-T to FDA
AN
Hemogenyx Files Complete Response to US FDA's Clinical Hold of Leukemia Treatment Application
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SILF Stock
  4. News Hemogenyx Pharmaceuticals Plc